In this prospective observational study, we sought to compare the efficacy and safety of docetaxel + oxaliplatin + capecitabine (DOC) with epirubicin + oxaliplatin + 5-fluouracil (EOF) as neoadjuvant chemotherapy (NAC) for clinical T3 or T4 non-metastatic gastric cancer (GC) patients.
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer / Petrioli, Roberto; Marrelli, Daniele; Roviello, Franco; D'Ignazio, Alessia; Torre, Pamela; Chirra, Martina; Savelli, Vinno; Ambrosio, Maria Raffaella; Francini, Guido; Calomino, Natale; Farsi, Marco; Vernillo, Remo; Francini, Edoardo. - In: SURGICAL ONCOLOGY. - ISSN 1879-3320. - 32:(2019), pp. 2-7. [10.1016/j.suronc.2019.10.002]
Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer
Francini, Edoardo
2019
Abstract
In this prospective observational study, we sought to compare the efficacy and safety of docetaxel + oxaliplatin + capecitabine (DOC) with epirubicin + oxaliplatin + 5-fluouracil (EOF) as neoadjuvant chemotherapy (NAC) for clinical T3 or T4 non-metastatic gastric cancer (GC) patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
Francini_Gastric-cancer.pdf
Open Access dal 24/12/2020
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
434.07 kB
Formato
Adobe PDF
|
434.07 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
